Ravulizumab (ALXN1210) [6], was subsequently developed through further engineering of eculizumab and is the first long-acting, C5 inhibiting antibody effective in patients with PNH [7], aHUS [8] and adult patients with gMG who are anti-acetyl choline receptor antibody positive [9]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.